Redcare Pharmacy Raises FY26 Outlook

(RTTNews) - Redcare Pharmacy N.V. (SAE1.F, RDC.DE) Monday raised its full-year 2026 guidance after reporting stronger-than-expected trading during the first two months of the second quarter, driven by accelerating growth in both prescription (Rx) and non-prescription (non-Rx) sales.

The online pharmacy operator said group revenue increased 20% year-over-year quarter-to-date, with growth accelerating compared with the first quarter of 2026. The DACH segment, comprising Germany, Austria and Switzerland, posted 21% revenue growth, supported by stronger non-Rx sales and continued momentum in prescription medicines.

In Germany, non-Rx growth accelerated to 14% year-over-year during the first two months of the quarter, compared with 9% growth in the first quarter. Total Rx sales increased 33%, while German Rx revenue surged 57%, up from 55% growth recorded in the first quarter.

The International segment maintained solid momentum, with revenue increasing 16% in April and May, matching the growth rate achieved in the first quarter.

The company also raised its German Rx revenue forecast to 680 million euros to 720 million euros, representing growth of 35% to 43%, and now expects an adjusted EBITDA margin of 2.5% to 3.0%, compared with its previous target of more than 2.5%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This data feed is not available at this time.